Clinical trial
A Study to Evaluate ALN-2232 in Participants With Obesity
Recruiting now · Phase 1, Phase 2 · 1 countries · Registry ID NCT07463846
Recruiting nowPhase 1, Phase 2Interventional
What this study is about
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 65 Years
SexAll
Healthy volunteersNot accepted
ConditionObesity
Full registry criteria
Inclusion Criteria: All Parts: * Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2 * Has a hemoglobin A1c (HbA1c) \<6.5% Exclusion Criteria: All Parts: * Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results * Receiving therapies for chronic weight management or antidiabetic medications Note: other protocol defined inclusion/exclusion criteria apply
Treatments and study arms
ALN-2232
Drug
ALN-2232 will be administered subcutaneously (SC)
Placebo
Drug
Placebo will be administered SC
Tirzepatide
Drug
Tirzepatide will be administered SC
Primary outcomes
Part A: Frequency of Adverse Events (AEs)Up to 12 months
Part B: Percent Change from Baseline in Body WeightBaseline up to Month 6
Part C: Percent Change from Baseline in Body WeightBaseline up to Month 6
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Clinical Trial Site🇨🇦 Mount Royal, Canada